menu
    • menu
    [{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Cryostem","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Rheos Medicines \/ Rheos Medicines","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Rheos Medicines"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Rheos Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Rheos Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Rheos Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Rheos Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Rheos Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Medivir","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rheos Medicines \/ Rheos Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Rheos Medicines \/ Rheos Medicines"}]

    Find Clinical Drug Pipeline Developments & Deals by Rheos Medicines

    Menu

    Rheos Medicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RHX-317

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rheos Medicines Announces Publication of New Data to Support Targeting MALT1 to Treat Autoimmune and Inflammat...

                            Details : RHX-317 targets MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1), a protein expressed exclusively in cells of immune system, designed to inhibit activity of multiple immune cell types, attenuating the inflammatory response in ac...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 05, 2022

                            Lead Product(s) : RHX-317

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RHX-317

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rheos Medicines Receives FDA “Study May Proceed” Letter to Initiate Phase 1 Clinical Study Under its Inves...

                            Details : A MALT1 inhibitor, RHX-317 is designed to inhibit the activity of multiple immune cell types, attenuating the inflammatory response in the activated immune system, for the treatment of autoimmune and inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 20, 2022

                            Lead Product(s) : RHX-317

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RHX-317

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rheos Medicines Presents New Data Supporting MALT1 Inhibition as Novel Strategy for Precision Medicine-Based A...

                            Details : RHX-317, is a novel, small molecule MALT1 inhibitor initially in development for the treatment of chronic GVHD. Preclinical data demonstrate MALT1 inhibition targets pathogenic activity of the activated immune system, showing efficacy in a model of cGVHD...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 13, 2021

                            Lead Product(s) : RHX-317

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RHX-317

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Recipient : Cryostem

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Rheos Medicines Forms Research Collaboration With CRYOSTEM to Evaluate MALT1‑Targeted Therapeutics for Graft...

                            Details : The goal of the collaboration is to provide biological resources from HSC patients in order to evaluate MALT1-targeted therapeutics, including Rheos’s lead product candidate, RHX-317, for Graft-versus-Host Disease, based on functional immunologic profi...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 27, 2021

                            Lead Product(s) : RHX-317

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Recipient : Cryostem

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Medivir

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Joint Patent Application For MALT1 Inhibitors Published

                            Details : The patent application is an outcome of the option agreement that was previously entered into between the two companies regarding Medivir’s preclinical MALT1 project.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 15, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Medivir

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RHX-317

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rheos Medicines to Present Data at ASH 2021 for MALT1 Inhibition for Treatment of Graft-Versus-Host Disease

                            Details : Rheos Medicines will present preclinical data showing the potential of RHX-317, a MALT1 inhibitors for the treatment of chronic Graft-Versus-Host Disease (GVHD) at the 63rd Annual Meeting of the American Society of Hematology.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 11, 2021

                            Lead Product(s) : RHX-317

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Rheos Medicines

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RHX-317

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rheos Medicines Presents Data Demonstrating Potential of MALT1 Inhibition as Novel Approach for the Treatment ...

                            Details : The results demonstrating MALT1 inhibition support Rheos’s lead product candidate, RHX-317, a novel, small molecule MALT1 inhibitor, that the company is initially developing for the treatment of chronic graft versus host disease (GVHD).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 11, 2021

                            Lead Product(s) : RHX-317

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth